Activating mutations of the GNAQ gene: A frequent event in primary melanocytic neoplasms of the central nervous system

Acta Neuropathologica

Volumn 119, Issue 3, 2010, Pages 317-323

  Küsters Vandevelde, Heidi V N ^a   Klaasen, Annelies ^b   Küsters, Benno ^b   Groenen, Patricia J T A ^b   Van Engen Van Grunsven, Ilse A C H ^b   Van Dijk, Marcory R C F ^c   Reifenberger, Guido ^d   Wesseling, Pieter ^a,b   Blokx, Willeke A M ^b  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Central nervous system; GNAQ; MAP kinase pathway; Melanocytoma; Primary melanocytic neoplasms

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PROTEIN GNAQ; RAS PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GRADING; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; GENE LOCATION; GENE SEQUENCE; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; MELANOMA; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE H RAS; ONCOGENE N RAS; PIGMENT DISORDER; POINT MUTATION; PRIMARY MELANOCYTIC NEOPLASM; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SOMATIC MUTATION;

ADULT; AGED; CENTRAL NERVOUS SYSTEM NEOPLASMS; CODON; DNA, NEOPLASM; FEMALE; GENES, RAS; GTP-BINDING PROTEIN ALPHA SUBUNITS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOCYTES; MELANOMA; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; TISSUE FIXATION;

EID: 77953020698     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-009-0611-3     Document Type: Article

References (34)

1. Balmaceda CM, Fetell MR, O'Brien JL, Housepian EH (1993) Nevus of Ota and leptomeningeal melanocytic lesions. Neurology 43:381-386.
2. Barbacid M (1987) ras genes. Annu Rev Biochem 56:779-827.
3. Bauer J, Kilic E, Vaarwater J, Bastian BC, Garbe C, de KA (2009) Oncogenic GNAQ mutations are not correlated with disease- free survival in uveal melanoma. Br J Cancer 101:813-815.
4. Bisceglia M, Carosi I, Fania M, Di CA, Lomuto M (1997) Nevus of Ota. Presentation of a case associated with a cellular blue nevus with suspected malignant degeneration and review of the literature. Pathologica 89:168-174.
5. Brat DJ, Perry A (2007) Melanocytic lesions. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. IARC, Lyon, pp 181-183.
6. Brat DJ, Giannini C, Scheithauer BW, Burger PC (1999) Primary melanocytic neoplasms of the central nervous systems. Am J Surg Pathol 23:745-754.
7. Bullard DE, Cox EB, Seigler HF (1981) Central nervous system metastases in malignant melanoma. Neurosurgery 8:26-30.
8. Burger PC, Scheithauer BW, Vogel FS (2009) Surgical pathology of the nervous system and its coverings. Churchill Livingstone, New York.
9. Casparie M, Tiebosch AT, Burger G et al (2007) Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 29:19-24.
10. Cruz F III, Rubin BP, Wilson D et al (2003) Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res 63:5761-5766.
11. Fecher LA, Amaravadi RK, Flaherty KT (2008) The MAPK pathway in melanoma. Curr Opin Oncol 20:183-189.
12. Goldgeier MH, Klein LE, Klein-Angerer S, Moellmann G, Nordlund JJ (1984) The distribution of melanocytes in the leptomeninges of the human brain. J Invest Dermatol 82:235-238.
13. Hocker T, Tsao H (2007) Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 28:578-588.
14. Horn EM, Nakaji P, Coons SW, Dickman CA (2008) Surgical treatment for intramedullary spinal cord melanocytomas. J Neurosurg Spine 9:48-54.
15. Jackson IJ (2004) The G-netics of dark skin. Nat Genet 36:935-936.
16. Kadonaga JN, Frieden IJ (1991) Neurocutaneous melanosis: definition and review of the literature. J Am Acad Dermatol 24:747-755.
17. Lamba S, Felicioni L, Buttitta F et al (2009) Mutational profile of GNAQQ209 in human tumors. PLoS One 4:e6833.
18. Livingstone E, Claviez A, Spengler D et al (2009) Neurocutaneous melanosis: a fatal disease in early childhood. J Clin Oncol 27:2290-2291.
19. Markby DW, Onrust R, Bourne HR (1993) Separate GTP binding and GTPase activating domains of a G alpha subunit. Science 262:1895-1901.
20. Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J (2002) Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression. Clin Cancer Res 8:3468- 3474.
21. Onken MD, Worley LA, Long MD et al (2008) Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 49:5230-5234.
22. Poynter JN, Elder JT, Fullen DR et al (2006) BRAF and NRAS mutations in melanoma and melanocytic nevi. Melanoma Res 16:267-273.
23. Retsas S, Gershuny AR (1988) Central nervous system involvement in malignant melanoma. Cancer 61:1926-1934.
24. Ross EM, Wilkie TM (2000) GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem 69:795-827.
25. Rutten I, Bolle S, Kaschten B, Stevenaert A, Deneufbourg JM, Deprez M (2005) Recurrent intracranial melanocytoma associated with a nevus of Ota. Acta Neurochir 147:313-315.
26. Saldanha G, Purnell D, Fletcher A, Potter L, Gillies A, Pringle JH (2004) High BRAF mutation frequency does not characterize all melanocytic tumor types. Int J Cancer 111:705-710.
27. Savitz MH (1987) Primary melanomas of the central nervous system. J Neurosurg 66:948.
28. Shin MK, Levorse JM, Ingram RS, Tilghman SM (1999) The temporal requirement for endothelin receptor-B signalling during neural crest development. Nature 402:496-501.
29. Skarli SO, Wolf AL, Kristt DA, Numaguchi Y (1994) Melanoma arising in a cervical spinal nerve root: report of a case with a benign course and malignant features. Neurosurgery 34:533-537.
30. Thomas NE (2006) BRAF somatic mutations in malignant melanoma and melanocytic naevi. Melanoma Res 16:97-103.
31. van Dongen JJ, Langerak AW, Bruggemann M et al (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 17:2257-2317.
32. Van Raamsdonk CD, Bezrookove V, Green G et al (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457:599-602.
33. Van Raamsdonk CD, Fitch KR, Fuchs H, de Angelis MH, Barsh GS (2004) Effects of G-protein mutations on skin color. Nat Genet 36:961-968.
34. Yazdi AS, Palmedo G, Flaig MJ et al (2003) Mutations of the BRAF gene in benign and malignant melanocytic lesions. J Invest Dermatol 121:1160-1162.